Trump Tariffs Target Pharma Sector As Markets Weigh Fed Policy Signals
President Donald Trump has announced a 100% import tariff on branded pharmaceuticals not manufactured in the United States. The new policy, set to take effect on October 1, 2025, is part of a broader trade offensive that also includes heavy trucks, kitchen cabinets, and upholstered furniture.
In a post on Truth Social, Trump stated, “Pharmaceutical imports will face a 100 percent tariff unless the companies behind them are actively building plants on American soil.” He added that the move was necessary for “National Security and other reasons.”
Announcement Sent Shockwaves Through Global Markets
AstraZeneca and GlaxoSmithKline (GSK), two of the UK’s largest drugmakers with major U.S. operations, saw immediate declines in London trading. Japanese firms, such as Sumitomo Pharma and Daiichi Sankyo, dropped between 2% and 5%, while European giants Bayer and Novo Nordisk also experienced a decline.
Pascal Chan, Vice President for Strategic Policy at the Canadian Chamber of Commerce, warned that “Immediate price hikes, strained insurance systems, hospital shortages, and the real risk of patients rationing or foregoing essential medicines” could follow.
According to U.S. Census Bureau data, the country imported nearly $233 billion worth of pharmaceutical and medicinal products in 2024. Analysts say the new tariffs could double costs for many drugs unless companies shift production to the U.S.
While The Tariff Threat Is Real, Not All Companies Are Equally Exposed
TD Cowen analyst Steve Scala noted, “AbbVie, Bristol Myers Squibb and Eli Lilly appear relatively well-positioned… while Novartis and Roche look more at risk”.
Jefferies analyst Michael Yee added that “Amgen and Biogen have the greatest exposure to tariffs among the biotech companies I cover.”
However, Biogen clarified in its Q1 earnings call that it expects “minimal exposure” due to its U.S.-based production and inventory positioning.
Pfizer CEO Albert Bourla responded to the tariff news by saying that “We will try to mitigate by transferring from manufacturing sites outside to manufacturing sites here (in the US)”.
Merck, meanwhile, has already committed $12 billion to expand domestic production, including a $1 billion investment in North Carolina for its Gardasil vaccine.
Fed Policy Signals Add to Market Uncertainty
While trade tensions rise, the Federal Reserve’s next move remains unclear. Strong economic data, like jobless claims falling to 218,000 and better-than-expected GDP revisions, have complicated expectations for rate cuts.
Chicago Fed President Austan Goolsbee cautioned that “We have begun to see goods prices showing through into higher inflation”. He warned against cutting rates too quickly.
In contrast, Trump appointee Miran has called for sharper rate cuts, exposing internal divisions within the Fed. Trump himself criticized Fed Chair Jerome Powell, saying that “There’s no inflation. We’re having unbelievable success”.
He also called Powell “incompetent” and pushed for interest rates to be lowered to 2%CoinGabbar.
Markets React: Selective Gains, Broad Caution
Despite the pharma sector’s decline, the FTSE 100 remained steady. It shows resilience through diversification. The FTSE 250 posted modest gains, supported by domestic factors.
Currency markets were calm, with the British pound holding around $1.33–1.34. The U.S. dollar initially surged but later dipped after the tariff news, with the DXY index falling to 98.4.
In the U.S., most S&P 500 sectors declined. However, energy gained 0.9% and tech stocks saw slight advances. Intel rose nearly 9% on news of talks with Taiwan Semiconductor Manufacturing Co.. However, CarMax dropped 20% after weak earnings.
Global Impact: Asia and Europe Feel the Pressure
Asian markets fell sharply, with Hong Kong’s Hang Seng down 1.3% and European pharma stocks retreating. The lack of clarity around what qualifies as “branded” or “patented” drugs added to investor anxiety.
Volvo, which already manufactures trucks in the U.S., saw modest gains, while Daimler Truck and Traton dropped over 3%.
Is It a Strategic Shift or Shock Therapy?
Trump’s tariff strategy is forcing pharmaceutical companies to rethink their global operations. Some firms may benefit from existing U.S. infrastructure. However, other companies face steep costs and supply chain disruptions. The Fed’s cautious stance makes things more complex. As Trump put it, “We’ll Earn Trillions from Tariffs, and We Have Our Own Oil”. This plan may work, but only if industries adapt quickly and the Fed makes smart decisions.
